GB202006093D0 - Composition - Google Patents
CompositionInfo
- Publication number
- GB202006093D0 GB202006093D0 GBGB2006093.5A GB202006093A GB202006093D0 GB 202006093 D0 GB202006093 D0 GB 202006093D0 GB 202006093 A GB202006093 A GB 202006093A GB 202006093 D0 GB202006093 D0 GB 202006093D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2006093.5A GB202006093D0 (en) | 2020-04-24 | 2020-04-24 | Composition |
CN202180044702.8A CN115916829A (en) | 2020-04-24 | 2021-04-23 | Compositions comprising IGE antibodies |
US17/919,589 US20230151090A1 (en) | 2020-04-24 | 2021-04-23 | Composition comprising an ige antibody |
AU2021260852A AU2021260852A1 (en) | 2020-04-24 | 2021-04-23 | Composition comprising an IgE antibody |
KR1020227038538A KR20230006824A (en) | 2020-04-24 | 2021-04-23 | Compositions comprising IGE antibodies |
CA3176300A CA3176300A1 (en) | 2020-04-24 | 2021-04-23 | Composition comprising an ige antibody |
MX2022013400A MX2022013400A (en) | 2020-04-24 | 2021-04-23 | Composition comprising an ige antibody. |
EP21721081.4A EP4139356A1 (en) | 2020-04-24 | 2021-04-23 | Composition comprising an ige antibody |
PCT/EP2021/060749 WO2021214329A1 (en) | 2020-04-24 | 2021-04-23 | Composition comprising an ige antibody |
JP2022564560A JP2023523264A (en) | 2020-04-24 | 2021-04-23 | Compositions containing IgE antibodies |
BR112022021499A BR112022021499A2 (en) | 2020-04-24 | 2021-04-23 | COMPOSITION COMPRISING AN IGE ANTIBODY |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2006093.5A GB202006093D0 (en) | 2020-04-24 | 2020-04-24 | Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
GB202006093D0 true GB202006093D0 (en) | 2020-06-10 |
Family
ID=71080097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB2006093.5A Ceased GB202006093D0 (en) | 2020-04-24 | 2020-04-24 | Composition |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB202006093D0 (en) |
WO (1) | WO2021214329A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022223784A1 (en) * | 2021-04-23 | 2022-10-27 | King's College London | Composition comprising an ige antibody |
EP4166569A1 (en) * | 2021-10-18 | 2023-04-19 | Fondazione IRCCS Istituto Nazionale dei Tumori | Antibodies directed against alpha-folate receptor |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
EP3275902A1 (en) | 2011-10-04 | 2018-01-31 | IGEM Therapeutics Limited | Ige anti-hmw-maa antibody |
TWI694836B (en) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | Antibody formulation |
-
2020
- 2020-04-24 GB GBGB2006093.5A patent/GB202006093D0/en not_active Ceased
-
2021
- 2021-04-23 WO PCT/EP2021/060749 patent/WO2021214329A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021214329A1 (en) | 2021-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB202004460D0 (en) | Herbical composition | |
GB202007377D0 (en) | Composition | |
EP4094582A4 (en) | Composition | |
GB202006093D0 (en) | Composition | |
GB202005911D0 (en) | Composition | |
GB202105455D0 (en) | Composition | |
GB202014635D0 (en) | Composition | |
GB202012895D0 (en) | Composition | |
GB202000619D0 (en) | Composition | |
EP4230692A4 (en) | Composition | |
GB202114569D0 (en) | Composition | |
GB202112763D0 (en) | Composition | |
GB202111898D0 (en) | Composition | |
GB202110358D0 (en) | Composition | |
GB202109550D0 (en) | Composition | |
GB202108511D0 (en) | Composition | |
GB202107377D0 (en) | Composition | |
GB202107382D0 (en) | Composition | |
GB202105744D0 (en) | Composition | |
GB202104499D0 (en) | Composition | |
GB202104498D0 (en) | Composition | |
GB202104395D0 (en) | Composition | |
GB202103434D0 (en) | Composition | |
GB202103441D0 (en) | Composition | |
GB202103439D0 (en) | Composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |